TABLE 2.

Clinical trials target cognitive enhancement for Alzheimer’s disease (AD) patients in 2021 in Clinicaltrials.gov.

NCT number	Phases	Interventions	Status	Conditions	Locations	Gender	Age (years)	Enrollment	Funder
NCT04308304	Phase 1	Drug: MK-1942; Drug: Donepezil; Drug: Placebo	Completed	AD	USA	All	50–85	27	Industry
NCT04249869	Phase 1, Phase 2	Drug: VGH-AD1	Unknown status	AD	China	All	≥65	28	Other
NCT04602624	Phase 2	Drug: SAGE-718	Completed	AD,CD,MD	USA	All	50–80	26	Industry
NCT02720445	Phase 2	Drug: Nicotine transdermal patch; Drug: Placebo patch	Recruiting	MCI	USA	All	55–90	380	Other| NIH
NCT04044131	Phase 2	Drug: Metabolic cofactor supplementation; Drug: Sorbitol	Unknown status	AD	Turkey	All	≥18	120	Other| Industry
NCT04601038	Phase 2	Drug: CORT108297; Drug: Placebo	Recruiting	AD,MCI	USA	All	≥55	52	Other
NCT03625401	Phase 2	Drug: AD-35 60 mg group; Drug: Placebo group	Unknown status	AD	China	All	50–85	55	Industry
NCT03090516	Phase 2, Phase 3	Drug: Ginkgo biloba dispersible tablets; Drug: Donepezil; Drug: Ginkgo biloba dispersible tablets and donepezil	Unknown status	AD	China	All	50–85	240	Other
NCT04229927	Phase 3	Drug: BPDO-1603	Recruiting	AD	China	All	≥45	712	Industry
NCT04661280	Phase 3	Drug: Donepezil	Recruiting	AD	France	All	≥50	240	Other
NCT04570085	Phase 3	Drug: Caffeine| Drug: Placebo	Recruiting	AD	France	All	≥50	248	Other
NCT03283059	Phase 3	Drug: Octohydroaminoacridine succinate; Drug: Aricept; Drug: Placebos	Unknown status	AD	China	All	50–85	600	Other, industry
NCT03116126	Phase 3	Drug: Guanfacine; Drug: Placebo	Recruiting	AD	UK	All	≥45	160	Other